ABC News
Turn on desktop notifications for breaking stories about interest?
OffOn
Earlier trials by Pfizer and Moderna didn t include virus variants.
• 6 min read
Single-dose vaccine effective against COVID-19 variants, data shows
The Food and Drug Administration announced that Johnson & Johnson’s one-shot vaccine meets the requirements of the emergency use authorization review process. Authorization could come on Friday.Phill Magakoe/AFP via Getty Images
Some have raised concerns that one of Johnson & Johnson s previously reported vaccine data points a 66% global efficacy in preventing moderately symptomatic disease doesn t seem as impressive as figures reported by Pfizer and Moderna, which exceeded 90% efficacy at preventing symptomatic COVID-19. But experts are quick to note that it may not be the best comparison: The Pfizer and Moderna clinical trials didn t take into account new variants and still had 100% effectiveness against hospitalizations and deaths.
Janssen/J&J COVID-19 Vaccine Cuts Transmission, New Data Show
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released
An investigational COVID-19 vaccine developed by Janssen Pharmaceuticals appears to be safe and effective at preventing moderate and severe COVID-19 in adults, according to an interim analysis of Phase 3 clinical data conducted Jan. 21. The vaccine, called Ad.26.COV2.S or JNJ-78436725, requires only a single injection and can be stored in a refrigerator for months.
The interim analysis assessed 468 cases of symptomatic COVID-19 among 44,325 adult volunteers in Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa, and the United States. The investigational vaccine was reportedly 66% effective at preventing the study’s combined endpoints of moderate and severe COVID-19 at 28 days post-vaccination among all volunteers, including those infected with an emerging viral variant. Moderate COVID-19 was defined as laboratory-confirmed SARS-CoV-2 plus either one of the following: evidence
Johnson & Johnson s COVID-19 Vaccine Results Are Better Than They May Sound Time 1/29/2021 © U. Baumgarten via Getty Images 2021 Ulrich Baumgarten
Johnson & Johnson’s Janssen Pharmaceutical Companies announced on Jan. 29 that its one-shot COVID-19 vaccine is 66% effective in protecting against disease, but 85% effective against preventing severe disease results that could make it especially valuable in the effort to vaccinate parts of the world with weak health care systems.
By comparison, the vaccines already authorized in the U.S. one from Moderna and one from Pfizer-BioNTech each require two doses, spaced three to four weeks apart. Janssen’s vaccine can also be stored in normal refrigerators, unlike Moderna’s and Pfizer-BioNTech’s, both of which need to be frozen. While the vaccines from Moderna and Pfizer-BioNTech are around 94%-95% effective in protecting against COVID-19, that’s after two doses of those shots, which are based on mRNA, a relatively new vaccine
vimarsana © 2020. All Rights Reserved.